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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:
Our main objective is to assess the test accuracy of any multidomain cognitive test delivered remotely for the diagnosis of any form of
dementia.
Our review will not be limited to a particular healthcare setting or a particular threshold score of index test.
Secondary objectives
• To describe the degree of agreement between a remotely delivered cognitive test and the same or a closely related test delivered in-
person when neither is assessed against a clinical dementia reference standard.
• To identify the quality and quantity of the research evidence describing test accuracy of remote testing.
• To identify sources of heterogeneity in the test accuracy described.
• To identify gaps in the evidence where further research is required.
Investigation of sources of heterogeneity
Heterogeneity is oLen seen in clinical test accuracy reviews (Deeks 2001). Important potential sources of heterogeneity will include the
case-mix of the population being assessed; clinical setting; person performing the assessment; platform used to administer the test (e.g.
standard telephone versus video call); threshold scores used to define test positivity; and the quality of the included papers. We will collect
data on all of these factors, and if data allow will explore their eNect using subgroup and sensitivity analyses as appropriate.
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B A C K G R O U N D
Assessment of cognition using a multidomain test can serve many
important purposes (Lin 2013). In clinical practice, cognitive testing
may form part of the assessment of the person with a suspected
cognitive syndrome, or the testing may be used as an initial triage
tool to identify those who need more specialist input. In research,
cognitive testing may be used to identify potential participants for
a study or as an assessment of treatment eNect in a clinical trial.
There are many multidomain cognitive assessment tools available
to the clinician (Harrison 2016). Indeed, in some areas there are
almost as many assessment tools as there are research studies
(Lees 2012). It is important to distinguish the short screening
tests that will be the focus of this review from more detailed
assessments that attempt a diagnostic formulation. Although there
is no consensus on the optimal cognitive assessment, certain tests
have greater visibility and traction in research and practice. An
important factor to consider when choosing a cognitive test is the
test’s accuracy for the detection of the condition of interest, for
example the accuracy of a screening test for detection of dementia.
In the Cochrane Dementia and Cognitive Improvement Group
(CDCIG), we have reviewed the literature and summarised the
accuracy of many of the commonly used cognitive screening tests,
including Folstein’s Mini-Mental State Examination (Creavin 2016),
Montreal Cognitive Assessment (Davis 2015), and Addenbrooke's
Cognitive Examination (Beishon 2019).
To date, our suite of diagnostic test accuracy (DTA) reviews have
been limited to in person, face-to-face assessment, as this is
the favoured clinical reference standard  and would be usual
practice in most services (Davis 2013). The current coronavirus
pandemic has caused a fundamental change in practice that no
one had anticipated. The emergency restrictions on movement
and social contact necessitated by the viral pandemic limit
the opportunity for in-person assessment. Clinical services and
research teams have responded, and increasingly consultations
are being performed remotely. Various cognitive screening tests
designed for administration over the telephone or via video-call are
available and could be well suited to the current situation (Elliott
2020). However, the diagnostic accuracy of these tools should not
be assumed, and we felt it was necessary to collate, appraise,
and present estimates of accuracy for papers describing the use
of remote cognitive testing. Remote testing can be performed
using the telephone, but increasing availability of audio-visual
technologies also allows for assessment using video-based calls or
other telehealth approaches. We are interested in both telephone
and video-based assessments, but will consider these technologies
separately.
Beyond the pandemic situation, there are other circumstances
in which remotely administered cognitive tests could be useful.
Many practitioners in remote and rural areas are already familiar
with using them for clinical purposes (Barth 2018). In the research
context, such tests may be the only feasible way to include cognitive
outcome measures in large pragmatic trials or observational
studies (Ritchie 2015).
Target condition being diagnosed
The condition of interest for this review is clinical dementia.
We recognise that cognitive testing may be used to inform
the diagnosis of other cognitive syndromes such as mild
cognitive impairment (MCI), but the condition of greatest
relevance is invariably clinical dementia. The dementia diagnosis
is operationalised in various classification systems, such as
the American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders (DSM) and the World Health
Organization’s International Classification of Diseases (ICD) (APA
2013; WHO 2010). Although there are some diNerences between
these classifications (e.g. the most recent DSM guidance suggests
use of the terms 'Major' and 'Mild Neurocognitive Disorder'
rather than dementia and MCI), they all describe dementia as a
progressive, irreversible condition characterised by impairments
in multiple cognitive domains suNicient to cause problems in
activities of daily living. Additional classifications exist to describe
pathological dementia subtypes, for example Alzheimer’s disease
or vascular dementia.
Dementia test accuracy studies have traditionally used the
paradigm of assessing a test of interest against a clinical dementia
reference standard (Takwoingi 2018). For this particular review,
with its focus on remote testing, we anticipate an alternative
but equally important study design – where the remote test is
compared against the usual, in-person administration of the same
test. Although ultimately the cognitive testing is being performed
to assess for a cognitive syndrome such as dementia, these papers
may not necessarily include any dementia diagnosis data. Even
without the dementia diagnosis, such papers can oNer useful
insights into the properties of remote testing compared to usual
face-to-face practice. So, whilst such analyses are not diagnostic
test accuracy, we will also review those papers that use a remote
versus face-to-face test comparison approach.
Index test(s)
Our index test of interest is any multidomain cognitive assessment
tool that is administered remotely, for example over the telephone
or via video call. We will consider these two technologies
separately.
We suspect that in most instances the test will be a variation of
standard face-to-face cognitive assessment, although content may
need to be modified for remote delivery. We are interested in real-
time assessment that involves someone administering and scoring
the test. Our remit will thus not extend to computer-based cognitive
gaming that purports to oNer an assessment, or online cognitive
questionnaires.
We anticipate that the review will include several diNerent tests.
If the data allow, there may be an opportunity for comparative
analyses of the accuracy of the various tests.
Clinical pathway
For consistency with other reviews and in keeping with usual
methods, we use the phrase ‘diagnostic test accuracy’ (Davis 2013).
However, we recognise that our index tests of interest are screening
in nature and not suNicient to make a diagnosis on their own. In
clinical practice the multidomain test is oLen the first step in a
detailed, multidisciplinary assessment that may also be informed
by assessments of function, collateral history, and radiological and
laboratory testing (Noel-Storr 2012).
The remote tests of interest are not exclusive to a particular
healthcare setting. Brief cognitive screening may be performed in
primary care to inform the need for onward referral to specialist
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services. In secondary care clinic settings, cognitive screening may
be performed as part of a diagnostic work-up, or to monitor
disease progression. All of these test scenarios could plausibly
be performed remotely, and indeed the current viral pandemic is
mandating this approach to testing. Prevalence of dementia will
vary by setting, and if data allow we will explore this as part of our
investigation of heterogeneity.
For inpatient secondary care services, cognitive screening oLen
forms part of the initial assessment of admissions to the general
hospital. Many countries recommend early cognitive screening of
certain groups such as unscheduled older adult admissions or
stroke survivors (Robinson 2015). In this situation, the purpose
of testing is to identify a cognitive baseline and assess for the
syndrome of delirium. This pathway is likely to remain an in-person
assessment by the admitting team, and so is unlikely to be included
in this review, but there will be no exclusions based on setting or
purpose.
Alternative test(s)
Another alternative to in-person cognitive assessment is a
questionnaire-based test (Harrison 2015), delivered either by post
on using online platforms. We will not consider questionnaire-
based approaches in this review, but hope to produce a separate
review on self-complete questionnaire-based assessments.
Rationale
The arguments for timely diagnosis of dementia have been made by
various professional societies and will not be rehearsed again here
(Robinson 2015). SuNice it to say, cognitive testing is fundamental
to the assessment of the person with a suspect cognitive problem.
Our motivation for this review is in response to the current global
viral pandemic, where best practice of in-person cognitive testing is
oLen not safe or possible. Clinical and research teams are having to
rapidly adapt to new ways of working, and we hope to provide an
evidence base to guide choice of testing.
O B J E C T I V E S
Our main objective is to assess the test accuracy of any
multidomain cognitive test delivered remotely for the diagnosis of
any form of dementia.
Our review will not be limited to a particular healthcare setting or a
particular threshold score of index test.
Secondary objectives
• To describe the degree of agreement between a remotely
delivered cognitive test and the same or a closely related test
delivered in-person when neither is assessed against a clinical
dementia reference standard.
• To identify the quality and quantity of the research evidence
describing test accuracy of remote testing.
• To identify sources of heterogeneity in the test accuracy
described.
• To identify gaps in the evidence where further research is
required.
Investigation of sources of heterogeneity
Heterogeneity is oLen seen in clinical test accuracy reviews (Deeks
2001). Important potential sources of heterogeneity will include the
case-mix of the population being assessed; clinical setting; person
performing the assessment; platform used to administer the test
(e.g. standard telephone versus video call); threshold scores used
to define test positivity; and the quality of the included papers. We
will collect data on all of these factors, and if data allow will explore
their eNect using subgroup and sensitivity analyses as appropriate.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Our primary interest will be cross-sectional studies, where the
index test(s) are administered alongside reference standard clinical
assessment.
As a secondary, exploratory analysis we also propose a review
of those papers where a remote assessment is compared to the
equivalent in-person test. These papers may or may not also have
information on reference standard dementia assessment. Where
data are available that are limited to comparison of remote and
in-person testing, we will include these studies but the proposed
analysis will diNer, recognising that these studies are assessing
correlation/agreement rather than diagnostics.
We will exclude case-control studies due to the inherent risk of
bias and inability to use these data to make any inferences about
population predictive value. For the same reasons, we will exclude
studies that use an enriched sample, for example studies that only
include participants who have a certain screening test score, or
where the reference standard assessment is limited to participants
with a particular cognitive profile.
Studies where the index test is compared against future
development of a cognitive syndrome (delayed-verification
studies) require a diNering review approach compared to the
traditional cross-sectional test accuracy study. We will not consider
delayed-verification studies in this review. We will not include any
study where the index and reference standard are administered
with more than one month between them, as such studies should
be considered prognostic. Studies where the delay between index
and reference is shorter are potentially eligible, and we will
consider the eNect of the delay as part of the 'Risk of bias'
assessment.
We will exclude studies with a small number of cases (fewer
than 10), as these studies are unlikely to meaningfully add to our
understanding of test accuracy and are prone to various selection
biases.
Participants
Our population of interest is any adult (age over 18 years) requiring
cognitive testing.
We will not include studies exclusively comprised of cognitively
normal  participants that are used to create normative values of
tests. For studies that compare a remote index to the equivalent
face-to-face version, formal cognitive status may be unknown. We
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will include these studies but will not combine them with studies
that assess accuracy against a clinical dementia reference standard.
We will not exclude papers on the basis of a selected population,
but where the population are not predominantly an older adult
group (e.g. studies in traumatic brain injury or in stroke), we will
note this and where possible explore case-mix as a source of
heterogeneity.
We will include studies conducted in any healthcare setting, and
explore setting as a source of heterogeneity where possible.
Index tests
Studies must include, not necessarily exclusively, a remote
cognitive assessment.
Remote testing involves real-time assessment by a tester in a
diNerent location to the person being tested. Any platform that
allows remote testing will be included, and we anticipate studies
using traditional telephone, smartphone, videoconferencing.
Assessments must be multidomain, as these are the tests used in
clinical practice. Tests of single cognitive domains such as memory
only or attention only will therefore not be included.
Included tests may be modifications of existing in-person tests or
bespoke assessments designed for remote use.
The assessment should be performed remotely, so we will not
include studies where, for example, the script of a telephone
interview is used in a face-to-face assessment.
Included tests should directly assess the person of interest.
We will thus not include informant-based tests such as AD-8
(Hendry 2019) or IQCODE (Harrison 2015). If a test includes
both informant responses and direct testing, and these data are
available separately, we will include the direct test data. Where
tests have contingent scoring, for example if a person scores above
a certain value then further testing is performed, we will assess
suitability for inclusion case by case, but will not pool these data
with other screening tests.
Where we are comparing a remotely delivered index test to an
in-person equivalent, we will include those tests from which
the remote assessment was derived. For example, the various
iterations of the Telephone Interview for Cognitive Status were
designed to emulate the Folstein Mini-Mental State Examination
(MMSE) (Brandt 1988), and so we will consider MMSE as a suitable
reference for comparison. For this second objective, we will
compare each index test to the same test administered face-to-
face. If an index test was modified from a face-to-face parent test
specifically for remote administration, then we will compare it with
that parent test.
We will not limit the review to a particular remote test strategy, and
anticipate including multiple index tests. If data allow, there may
be an opportunity to perform indirect comparisons of estimates
of accuracy of various remote tests, but these analyses will be
exploratory rather than definitive (Owen 2018).
Our focus for this review is accuracy of testing. We will formally
assess whether remote testing is feasible, acceptable, or suitable for
the populations being tested, although some of these factors may
be relevant to our internal and external validity assessments.
Target conditions
We will consider papers reporting any clinical diagnosis of
dementia. Dementia diagnosis may be undiNerentiated, or a
particular subtype may be specified. Classifying dementia by
subtype is not required for inclusion, but where available these data
will be recorded.
Reference standards
Our reference standard will be a clinical diagnosis of dementia.
Within the clinical diagnosis rubric, we will include all-cause
(unspecified) dementia, using any recognised diagnostic criteria,
for example ICD-10 or DSM-IV. For the purposes of this review,
and in keeping with other Cochrane Diagnostic Test Accuracy
Reviews, we will consider structured interview assessments such
as Clinical Dementia Rating (CDR) as diagnostic (Davis 2013).
Dementia diagnoses may specify a pathological subtype, and we
will include all dementia subtypes in this review. We will not include
the cognitive syndrome of delirium in the review (Hendry 2016),
and will assume that in the process of making the clinical dementia
diagnosis, any reversible causes of cognitive impairment would
have been excluded.
Studies that make a postmortem diagnosis or base diagnosis
on imaging or other biomarkers without corresponding
comprehensive clinical assessment will not be eligible.
We will not set any limits in relation to severity or stage of dementia.
If data are available from suNicient studies, we will explore the
severity of dementia as a potential source of heterogeneity.
As a secondary, exploratory analysis, we also propose a review
of those papers where a remote assessment is compared to the
equivalent in-person test. These papers may or may not also have
information on reference standard dementia assessment. Where
data limited to comparison of remote and in-person testing are
available, we will not use the index versus reference standard
paradigm, but will describe agreement or correlation between the
tests.
Search methods for identification of studies
Electronic searches
We will search MEDLINE (Ovid SP), Embase (Ovid SP), Science
Citation Index (ISI Web of Knowledge), PsycINFO (Ovid SP),
LILACS (Latin American and Caribbean Health Science Information
database) (BIREME), and US National Institutes of Health
Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov/)
databases. Each source will be searched from inception to the
present. See Appendix 1 for a proposed draL strategy to be run
in MEDLINE (OvidSP). We will design similarly structured search
strategies using search terms appropriate for each database. We
will use controlled vocabulary such as MeSH terms and EMTREE
where appropriate. In the searches developed, we will make no
attempt to restrict studies on the basis of sampling frame or
setting. This approach is intended to maximise sensitivity and allow
for inclusion on the basis of population-based sampling to be
assessed at screening (see Selection of studies). We will not use
search filters (collections of terms aimed at reducing the number
needed to screen) as an overall limiter because those that are
published have not proved sensitive enough (Whiting 2008). We
will not apply any language restriction to the electronic searches,
using translation services as needed. We will search the ALOIS, the
Diagnostic test accuracy of remote, multidomain cognitive assessment (telephone and video call) for dementia (Protocol)
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CDCIG Specialized Register, which includes both intervention and
diagnostic test accuracy studies in dementia. We will not search the




Data collection and analysis
Selection of studies
Following searching, titles from various databases will be collated
in Covidence soLware (Covidence 2020). A single review author will
perform a ‘first pass’ review, removing clearly irrelevant titles, then
a minimum of two review authors will independently assess studies
for eligibility.
For consistency with our other DTA titles, we will adopt a
hierarchical approach to exclusion, first excluding on the basis of
index test and reference standard, and then on the basis of study
methods (case-control, size), and then on the basis of any other
reason.
Where a potentially relevant paper is missing data needed for
analyses, we will contact the primary author by email twice. If the
authors do not respond, or the relevant data are not available, we
will not include data from this study and label as 'data not suitable
for analysis'. If the same dataset is presented in more than one
paper, we will include the primary paper but make reference to
other papers if they contain relevant additional information.
Where studies are described in abstract form, we will contact the
lead author(s) to ask if the full paper is published. We will limit
the studies included to those published in peer-reviewed scientific
journals.
We will detail the study selection process in a PRISMA flow diagram.
Data extraction and management
Two review authors will independently extract data from eligible
papers onto a bespoke data extraction form. The form will describe
population tested, purpose/setting of testing, test(s) administered,
details of person performing testing, and details of reference
standard assessment. We will derive components of the 2x2 table
and prevalence figures.
We will pilot the data extraction form on two papers and make
any required changes. Following data extraction, the two review
authors will compare their findings and discuss and resolve any
disagreements, with recourse to a senior test accuracy review
author as needed.
Where a test assigns a score and accuracy data are given for a
variety of threshold scores, we will collect all of these data in
the first instance. Primary analyses will be limited to performance
at the standard threshold for that test (where a standard exists).
Exploratory analyses will describe accuracy at other thresholds.
Assessment of methodological quality
Paired, independent raters blinded to each other’s scores will
assess risk of bias (internal validity) and generalisability (external
validity) using the QUADAS-2 tool (www.bristol.ac.uk/population-
health-sciences/projects/quadas/quadas-2/).
QUADAS-2 assessment covers issues relating to patient selection,
index test, reference standard, and participant flow. Each domain
is assessed for issues related to risk of bias; the first three domains
are also assessed for generalisability concerns. Our group has
considerable experience using the QUADAS-2 tool. For previous DTA
reviews, we convened a group with expertise in test accuracy and
dementia to tailor the QUADAS-2 approach to the field of dementia
studies. Through this work we have operationalised scoring rules
for item- and domain-level QUADAS-2 assessment and modified
the generic QUADAS-2 question stems to cover issues pertinent to
cognitive testing (Appendix 2) (Davis 2013).
QUADAS-2 results will be presented as graphical displays and as a
narrative within the text. If data allow, we will perform a sensitivity
analysis limiting to those papers with low concern for risk of bias
across all the QUADAS domains.
Statistical analysis and data synthesis
Our primary analysis of interest is accuracy of the various
remote assessments against the dichotomous outcome variable
'dementia/no dementia'. To explore this, we will apply the
recommended Cochrane framework treating each test separately.
For each test, where data allow, we will extract data to populate
a standard 2x2 data table of binary test results (above and below
threshold score) cross-classified against binary reference standard.
From this table we will calculate sensitivities and specificities, with
95% confidence intervals, at individual test level for thresholds
of interest. Primary thresholds of interest will be based on the
thresholds proposed in the original paper describing the study,
unless there is a consensus agreed upon threshold that is used in
practice and diNers from the original threshold described. We will
present these study results graphically in a forest plot of sensitivity
and corresponding specificity. We will perform these first analyses
with standard Review Manager 5 soLware (Review manager 5.3
2020).
Where there are more than two studies describing a test with
the same threshold value, we will attempt quantitative meta-
analysis. In the first instance we will create summary estimates
of sensitivity and specificity using random-eNects models and the
bivariate approach. We will use bespoke soLware MetaDTA for
this (Freeman 2019). Our approach to analysis assumes that the
tests will use a common threshold to define a test positive case. If
multiple thresholds are described for a single test, we will explore
the potential for analysis using the summary receiver operating
characteristic curve (SROC) approach. We recognise that there are
new approaches to studies with diNerent thresholds in the same
study which make better use of the study-level data (Jones 2019).
Regardless of approach used, we will create summary estimates
with corresponding confidence intervals and range of maximum
and minimum input sensitivity and specificity.
For assessment of remote versus in-person testing, if data are
available as correlations or reliability or agreement measures, we
will tabulate these and describe them in the narrative of the review
but we will not attempt to create summary estimates. If scores are
presented, we will describe scores and the proportion classified as
having cognitive impairment for each test.
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Investigations of heterogeneity
We will not quantify statistical heterogeneity for these DTA
analyses. As a measure of the uncertainty around any summary
estimate, we will present both 95% confidence and prediction
intervals.
We will review forest plots of sensitivity and specificity looking for
outliers.
Assuming that heterogeneity is present and that data allow, we
will perform subgroup analyses to explore potential areas of
heterogeneity that are common to DTA studies in the dementia
field.
We will assess:
• populations tested, performing subgroup analyses if specific
disease groups feature in the included papers (e.g. traumatic
brain injury, stroke), or if specific healthcare settings feature (e.g.
secondary care clinics, where prevalence of disease will diNer to
other settings such as primary care);
• technical features of the testing strategy (platform used for
delivering the test; language of testing; person performing
testing);
• clinical criteria used to reach dementia diagnosis (e.g. ICD-10;
DSM-IV) and the methodology used to reach dementia diagnosis
(e.g. individual assessment; group (consensus) assessment).
Sensitivity analyses
Where appropriate (i.e. if not already explored in our analyses of
heterogeneity) and as data allow, we will explore the eNect of
methodological aspects of the included studies. In the first instance
we will run a sensitivity analysis limited to studies at low risk of bias.
Assessment of reporting bias
We will not perform a quantitative assessment of reporting bias. We
recognise that debate remains around the most robust approach
to assessment of reporting bias in DTA (Wilson 2015), and there is
uncertainty on how to apply standard approaches such as funnel
plots (Annefloor van Enst 2014).
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
 
1 exp DEMENTIA/
2 major cognitive disorder.ti,ab.
3 alzheimer*.ti,ab.
4 dement*.ti,ab.
5 ((lewy adj2 bod*) or LBD or DLB).ti,ab.
6 (FTLD or frontotemp*).ti,ab.
7 or/1-6
8 exp Neuropsychological Tests/
9 exp Cognition Disorders/di [Diagnosis]
10 ((cognit* or memor* or neuropsychological*) adj3 (assess* or test* or task* or performance* or decline* or function*)).ti,ab.
11 MoCA.ti,ab.
12 MMSE.ti,ab.
13 "Mini-mental State Examination".ti,ab.
14 "Brief Screen for Cognition Impairment".ti,ab.
15 "Memory and Ageing Telephone Screen".ti,ab.
16 "Telephone Cognitive Assessment Battery".ti,ab.
17 "Short Portable Mental Status Questionnaire".ti,ab.
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18 "Telephone Modified Mini- Mental state exam".ti,ab.
19 "Telephone administered Minnesota Cognitive Acuity Screen".ti,ab.
20 "Blessed Telephone Information Memory Concentration Test".ti,ab.





26 "Telephone Interview for Cognitive Status".ti,ab.
27 or/8-26













41 (remote* adj (test* or diagnos* or consult* or deliver*)).ti,ab.
42 "mobile tablet".ti,ab.
43 or/29-42
44 28 and 43
 
 
Appendix 2. QUADAS-2 anchoring statements
We provide some core anchoring statements for quality assessment of diagnostic test accuracy reviews of neuropsychological tests in
dementia. These statements are designed for use with the QUADAS-2 tool and were derived during a two-day, multidisciplinary focus
group in 2010. If a QUADAS-2 signalling question for a specific domain is answered 'yes', the risk of bias can be judged to be 'low'. If a
question is answered 'no', this indicates a risk of potential bias. The focus group was tasked with judging the extent of the bias for each
domain. During this process, it became clear that certain issues were key to assessing quality, whilst others were important to record but
were less important for assessing overall quality. To assist, we describe a 'weighting' system. When an item is weighted 'high risk', that
section of the QUADAS-2 results table is judged to have a high potential for bias if a signalling question is answered 'no'. For example, in
dementia diagnostic test accuracy studies, ensuring that clinicians performing dementia assessment are blinded to results of the index
test is fundamental. If this blinding was not present, the item on the reference standard should be scored 'high risk of bias', regardless of
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the other contributory elements. When an item is weighted 'low risk', it is judged to have a low potential for bias if a signalling question for
that section of the QUADAS-2 results table is answered 'no'. Overall bias will be judged on whether other signalling questions (with a high
risk of bias) for the same domain are also answered 'no'. In assessing individual items, a score of 'unclear' should be given only if there is
genuine uncertainty. In these situations, the review authors will contact the relevant study teams for additional information.
Anchoring statements to assist with 'Risk of bias' assessment
Domain 1: Patient selection
Risk of bias: could the selection of patients have introduced bias? (high/low/unclear)
Was a consecutive or random sample of patients enrolled? When sampling is used, the methods least likely to cause bias are consecutive
sampling and random sampling, which should be stated or described, or both. Non-random sampling or sampling based on volunteers is
more likely to be at high risk of bias. Weighting: high risk of bias
Was a case-control design avoided? Case-control study designs have a high risk of bias, but are sometimes the only studies available,
especially if the index test is expensive or invasive, or both. Nested case-control designs (systematically selected from a defined population
cohort) are less prone to bias, but they will still narrow the spectrum of patients that receive the index test. Study designs (both cohort and
case-control) that may also increase bias are those designs in which the study team deliberately increases or decreases the proportion of
participants with the target condition, for example a population study may be enriched with extra dementia participants from a secondary
care setting. Weighting: high risk of bias
Did the study avoid inappropriate exclusions? The study will be automatically graded as unclear if exclusions are not detailed (pending
contact with study authors). When exclusions are detailed, we will grade the study as 'low risk' if we feel that the exclusions are appropriate.
Certain exclusions common to many studies of dementia are medical instability, terminal disease, alcohol/substance misuse, concomitant
psychiatric diagnosis, and other neurodegenerative condition. However, if 'diNicult to diagnose' groups are excluded, this may introduce
bias, so exclusion criteria must be justified. For a community sample, we would expect relatively few exclusions. We will label post hoc
exclusions as 'high risk' of bias. Weighting: high risk of bias
Applicability: are there concerns that the included patients do not match the review question? (high/low/unclear)
The included patients should match the intended population as described in the review question. If not already specified in the review
inclusion criteria, the setting will be particularly important – the review authors should consider population in terms of symptoms,
pretesting, and potential disease prevalence. We will classify studies that use very selected participants or subgroups as low applicability,
unless they are intended to represent a defined target population, for example people with memory problems referred to a specialist and
investigated by lumbar puncture.
Domain 2: Index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high/low/unclear)
Were the index test results interpreted without knowledge of the reference standard? Terms such as 'blinded' or 'independently and
without knowledge of' are suNicient; full details of the blinding procedure are not required. This item may be scored as 'low risk'
if it is explicitly described, or if there is a clear temporal pattern to the order of testing that precludes the need for formal blinding
(e.g. all (neuropsychological test) assessments were performed before the dementia assessment). As most neuropsychological tests are
administered by a third party, knowledge of dementia diagnosis may influence their ratings; tests that are self-administered, for example
by using a computerised version, may have less risk of bias. Weighting: high risk
Were the index test thresholds prespecified? For neuropsychological scales, there is usually a threshold above which participants are
classified as 'test positive'; this may be referred to as threshold, clinical cut-oN, or dichotomisation point. DiNerent thresholds are used in
diNerent populations. A study is classified as at higher risk of bias if the authors define the optimal cut-oN post hoc based on their own
study data. Certain papers may use an alternative methodology for analysis that does not use thresholds; these papers should be classified
as not applicable. Weighting: low risk
Were suNicient data on (neuropsychological test) application given for the test to be repeated in an independent study? Particular points
of interest include method of administration (e.g. self-completed questionnaire versus direct-questioning interview), nature of informant,
and language of assessment. If a novel form of the index test is used, for example a translated questionnaire, details of the scale should be
included and a reference given to an appropriate descriptive text, and evidence of validation should be provided. Weighting: low risk
Applicability: are there concerns that the index test, its conduct, or its interpretation may diHer from the review question? (high/low/unclear)
Variations in the length, structure, language, and/or administration of the index test may all aNect applicability if they diNer from those
specified in the review question.
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Domain 3: Reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? (high/low/unclear)
Is the reference standard likely to correctly classify the target condition? Commonly used international criteria that can assist with
clinical diagnosis of dementia include those detailed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and the
International Classification of Diseases (ICD-10). Criteria specific to dementia subtypes include but are not limited to the National Institute
of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
for Alzheimer’s dementia; McKeith criteria for Lewy body dementia; Lund criteria for frontotemporal dementia; and National Institute of
Neurological Disorders and Stroke and Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN)
criteria for vascular dementia. When the criteria used for assessment are unfamiliar to the review authors and the Cochrane Dementia and
Cognitive Improvement Group, this item should be classified as 'high risk of bias'. Weighting: high risk
Were the reference standard results interpreted without knowledge of the results of the index test? Terms such as 'blinded' or 'independent'
are suNicient; full details of the blinding procedure are not required. This may be scored as 'low risk' if explicitly described, or if a clear
temporal pattern to the order of testing is evident (e.g. all dementia assessments performed before (neuropsychological test) testing).
Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing are
usual components of clinical assessment for dementia; however, specific use of the scale under review in the clinical dementia assessment
should be scored as high risk of bias. Weighting: high risk
Was suNicient information on the method of dementia assessment given for the assessment to be repeated in an independent study?
Particular points of interest for dementia assessment include the training/expertise of the assessor; whether additional information
(e.g. neuroimaging; other neuropsychological test results) was available to inform the diagnosis; and whether this was available for all
participants. Weighting: variable risk, but high risk if method of dementia assessment not described
Applicability: are there concerns that the target condition as defined by the reference standard does not match the review question? (high/low/
unclear)
There exists the possibility that some methods of dementia assessment, although valid, may diagnose a smaller or larger proportion of
participants with disease than in usual clinical practice. In these instances, the item should be rated 'poor applicability'.
Domain 4: Patient flow and timing (N.B. refer to, or construct, a flow diagram)
Risk of bias: could the patient flow have introduced bias? (high/low/unclear)
Was there an appropriate interval between the index test and the reference standard? For a cross-sectional study design, the potential
exists for the participant to change between assessments; however, dementia is a slowly progressive disease that is not reversible. The
ideal scenario would be a same-day assessment, but longer periods of time (e.g. several weeks or months) are unlikely to lead to a high risk
of bias. For delayed-verification studies, the index and reference tests are necessarily separated in time, given the nature of the condition.
Weighting: low risk
Did all participants receive the same reference standard? In some scenarios, participants who score 'test positive' on the index test have a
more detailed assessment for the target condition. When dementia assessment (or the reference standard) diNers between participants,
this should be classified as high risk of bias. Weighting: high risk
Were all participants included in the final analysis? Attrition will vary with study design. Delayed-verification studies will have higher
attrition than cross-sectional studies because of mortality, and this is likely to be greater in participants with the target condition. Dropouts
(and missing data) should be accounted for. Attrition that is higher than expected (compared with other similar studies) should be treated
as high risk of bias. We have defined a cut-oN of greater than 20% attrition as being high risk, but this will be highly dependent on the
length of follow-up in individual studies. Weighting: high risk
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